Globitair

Leader meetingsStock market

AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

South China Morning PostPeople's Republic of China

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would...

Read the full story at South China Morning PostOpen in the live monitor

On the map

Related discussion groups

No group discusses this yet. Start a discussion group and attach this story.

More news about People's Republic of China

More on Leader meetings